CIGB-258 immunomodulatory peptide: a novel promising treatment for critical and severe COVID-19 patients
Dominguez Horta, M. d. C.
Show abstract
This study characterizes the first clinical application of CIGB-258 in COVID-19 patients. CIGB-258 is an immunoregulatory peptide, derived from the cellular heat shock protein 60 (HSP60). Sixteen patients with COVID-19 in serious (31%) or critical (69%) conditions were included in this study. All critically ill patients recovered from the respiratory distress condition. Two of these patients had a fatal outcome due to nosocomial infections.The five seriously ill patients considerably improved. C-reactive protein (CRP) and interleukin-6 (IL-6) levels significantly decreased during treatment. CIGB-258 seems to be an effective and safe treatment option in COVID-19 patients under cytokine storm. TRIAL REGISTRATION: RPCEC00000313
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Apoptotic cells for therapeutic use in cytokine storm associated with sepsis 92%
- Prophylactic treatment of Glycyrrhiza glabra mitigates COVID-19 pathology through inhibition of pro-inflammatory cytokines in the hamster model and NETosis. 92%
- The inhibition of Macrophage Migration Inhibitory Factor by ISO-1 attenuates trauma-induced multi organ dysfunction in rats 92%
Similar papers in this journal
- Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study 92%
- Treatment with human umbilical cord-derived mesenchymal stem cells for COVID-19 patients with lung damage: a randomised, double-blind, placebo controlled phase 2 trial 90%
- Safety and immunogenicity of a heterologous boost with a recombinant vaccine, NVSI-06-07, in the inactivated vaccine recipients from UAE: a phase 2 randomised, double-blinded, controlled clinical trial 90%
Similar papers in this journal
- Novel prognostic determinants of COVID-19-related mortality: a pilot study on severely-ill patients in Russia 93%
- SARS-CoV-2 infection induces mixed M1/M2 phenotype in circulating monocytes and alterations in both dendritic cell and monocyte subsets 91%
- LRRC33 is a novel binding and regulating protein of TGF-β1 function in human acute myeloid leukemia cells 91%
Similar papers in this journal
- A retrospective study evaluating efficacy and safety of compassionate use of tocilizumab in 13 patients with severe-to-critically ill COVID-19: analysis of well-responding cases and rapidly-worsening cases after tocilizumab administration 93%
- Jinhua Qinggan Granules for Nonhospitalized COVID-19 Patients: a Double-Blind, Placebo-Controlled, Randomized Controlled Trial 93%
- Comparing COVID-19 and influenza presentation and trajectory 90%
Similar papers in this journal
- Etrinabdione (VCE-004.8), a B55a activator, promotes angiogenesis and arteriogenesis in critical limb ischemia. 90%
- Integration of Machine Learning to Identify Diagnostic Genes in Leukocytes for Acute Myocardial Infarction Patients 90%
- A consideration of publication-derived immune-related associations in Coronavirus and related lung damaging diseases 89%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.